TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
MENLO PARK, Calif., Dec. 06, 2017 -- Geron Corporation (Nasdaq:GERN) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017. The presentation will begin at 8:30 a.m. ET.
Dr. Azra Raza, M.D., Professor of Medicine and Director of the Myelodysplastic Syndromes (MDS) Center at New York-Presbyterian/Columbia University Medical Center in New York City, will present data from Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of the telomerase inhibitor imetelstat in patients with lower risk MDS being conducted by Janssen Research & Development, LLC. These data have been accepted as a poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
A live audio webcast of the presentation will be available through the Investors section of Geron’s website (www.geron.com) under Events. Following the live presentation, the webcast will be archived and available for replay for a period of 30 days.
To attend the meeting in person, please send an email to Gitanjali Jain Ogawa at The Trout Group ([email protected]) for further information.
About the Collaboration with Janssen
On November 13, 2014, Geron entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses. All regulatory, development, manufacturing and promotional activities related to imetelstat are being managed through a joint governance structure, with Janssen responsible for these activities.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACTS:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
[email protected] or [email protected]
Gitanjali Jain Ogawa
The Trout Group
646-378-2949
[email protected]
